• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board

    Investing News Network
    Jun. 23, 2016 08:40AM PST
    Genetics Investing

    ANN ARBOR, Mich.–(BUSINESS WIRE)–Millendo Therapeutics, Inc., a company developing novel therapies for endocrine diseases caused by hormone dysregulation, today announced the appointment of James Hindman as an independent board member and chairperson of its audit committee. In addition, Millendo has appointed current board member and Partner of New Enterprise Associates, Inc., Carol Gallagher, Pharm.D., as …

    ANN ARBOR, Mich.–(BUSINESS WIRE)–Millendo
    Therapeutics, Inc.
    , a company developing novel therapies for
    endocrine diseases caused by hormone dysregulation, today announced the
    appointment of James Hindman as an independent board member and
    chairperson of its audit committee. In addition, Millendo has appointed
    current board member and Partner of New Enterprise Associates, Inc.,
    Carol Gallagher, Pharm.D., as Chairperson of the Board.
    “Jim brings a wealth of financial knowledge and industry experience to
    Millendo from his years of senior leadership in pharma and biologics,”
    said Julia C. Owens, Ph.D., President and Chief Executive Officer of
    Millendo. “We welcome Jim’s expertise as he will be instrumental in
    helping to shape our strategy and achieve our mission to develop and
    deliver disease-modifying treatments for endocrine diseases caused by
    hormone dysregulation.”
    “Carol has been a key supporter and champion of Millendo since joining
    our board soon after our Series A financing,” Owens continued. “We are
    delighted that she has assumed the role of Chairperson and will continue
    her service on and leadership of the Board.”
    Mr. Hindman most recently served as Executive Vice President of Finance
    and Business Development and Chief Financial Officer at Allergan, Inc.,
    where, under his leadership, the company achieved its most robust
    financial performance in Allergan’s 64-year history. Mr. Hindman was
    also instrumental in facilitating the company’s largest restructuring,
    creating $20B in shareholder value that ultimately led to Actavis’
    acquisition of Allergan in 2015 and the creation of one of the top ten
    global pharmaceutical firms. During his 30-year tenure at Allergan, Mr.
    Hindman held various senior leadership positions including Executive
    Vice President of Finance and Business Development and Chief Financial
    Officer, and Senior Vice President, Finance and Controller, and was
    responsible for strategic and financial functions including treasury,
    investor relations, risk, controller, financial reporting, SEC
    compliance, audits, acquisitions and divestitures, and strategic
    planning. Additionally, he served as President of the Allergan
    Foundation from 2009-2015. Mr. Hindman earned his MBA from Pepperdine
    University and a B.S. in accounting from Loyola Marymount University. He
    currently serves as Director of NeuroSigma, Inc. and is a member of the
    Loyola Marymount University Board of Trustees.
    “It is an honor to join the Millendo Board of Directors at such an
    exciting time in the Company’s growth,” said Mr. Hindman. “I look
    forward to working with the Millendo team to deliver novel treatment
    options for patients with endocrine diseases for which there are
    currently limited or no approved treatment options. The strength of both
    the company’s pipeline and leadership team are impressive and a
    testament to Millendo’s success thus far,” Hindman continued. “I am
    excited to have the opportunity to contribute my experience and
    expertise to the Company’s future achievements and continue to advance
    important new treatments for endocrine diseases.”
    About Millendo Therapeutics, Inc.
    Millendo Therapeutics is
    focused on developing a portfolio of disease-modifying treatments for
    endocrine diseases caused by hormone dysregulation. Our product
    candidates seek to improve the quality of life for patients with orphan
    and specialty diseases with limited or no approved treatment options.
    Our clinical programs are designed to address:

    • Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease
      in women
    • Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of
      cortisol synthesis
    • Endogenous Cushing’s Syndrome (CS) – a condition resulting from
      chronic cortisol excess
    • Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the
      adrenal cortex

    Our experienced team is committed to bringing these first-in-class
    therapies to market.
    www.millendo.com

    leadership teambusiness developmentboard of directorspharmaceutical firms
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×